Early Phase Clinical Trial to Test the Feasibility of an ACT-based Physical Activity Promotion Program for Adults With Depressive Symptoms

July 18, 2022 updated by: David M. Williams, Brown University
The goal of the proposed project is to conduct a feasibility clinical trial comparing group-based acceptance and commitment therapy for physical activity, (ACT; ACTivity) to a time- and attention-matched standard PA intervention (i.e., PA education, goal-setting, and self-monitoring) plus relaxation training comparison condition (Relaxercise) among 60 low-active adults (ages 18-65) with elevated depressive symptoms. Participants will be randomized to treatment condition, followed for 6 months, including the 8-week treatment. Participants will be randomized 1:1 to treatment condition, followed for 6 months, including the 8-week treatment, and receive a 6-month YMCA membership to equate access to PA facilities.

Study Overview

Status

Recruiting

Conditions

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Rhode Island
      • Providence, Rhode Island, United States, 02912
        • Recruiting
        • Brown University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Elevated depressive symptoms (CES-D score of greater than or equal to 10)
  • Low-active (less than 60 minutes per week of moderate intensity PA)
  • Willing and able to attend weekly virtual video sessions via Zoom

Exclusion Criteria:

  • Regular mindfulness meditation practice (more than once per week)
  • Body Mass Index (BMI) less than 18.5 or greater than 40
  • History or presence of any condition that may limit or substantially increase the risks of physical activity
  • Active suicidal thoughts or behaviors
  • Currently participating in any exercise or weight-loss research studies
  • Household member is participating in this study
  • Does not have a Rhode Island mailing address OR if only Rhode Island mailing address is a PO box
  • Unable to receive materials in the mail at residential mailing address
  • Does not plan to live in Rhode Island for the next 6 months
  • Unable to speak, read, and/or write fluently in English

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ACTivity
Acceptance and Commitment Therapy for physical activity promotion plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
Acceptance and Commitment Therapy for physical activity promotion plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
Active Comparator: Relaxercise
Relaxation training plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
Relaxation training plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Accelerometry
Time Frame: Baseline, Post-Treatment (8 weeks), 6-months
Minutes of physical activity weighted by intensity, expressed in metabolic equivalent (MET) minutes per week as determined by accelerometers (Actigraph [model wGT3x-BT]) worn during one-week periods.
Baseline, Post-Treatment (8 weeks), 6-months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Self-report physical activity (Godin)
Time Frame: Baseline, Mid-Treatment (4 weeks) Post-Treatment (8 weeks), 6-months
Self-reported minutes of leisure time physical activity per week weighted by intensity
Baseline, Mid-Treatment (4 weeks) Post-Treatment (8 weeks), 6-months
Change in Self-reported depression symptoms (CES-D)
Time Frame: Baseline, Mid-Treatment (4 weeks) Post-Treatment (8 weeks), 6-months
Score on the Center for Epidemiological Studies Depression Scale (CES-D)
Baseline, Mid-Treatment (4 weeks) Post-Treatment (8 weeks), 6-months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Physical activity values clarification (valuing questionnaire)
Time Frame: Baseline, Mid-Treatment (4 weeks) Post-Treatment (8 weeks), 6-months
Measures how a person's values align with physical activity
Baseline, Mid-Treatment (4 weeks) Post-Treatment (8 weeks), 6-months
Change in Acceptance of physical activity-related distress (Physical Activity Acceptance Questionnaire)
Time Frame: Baseline, Mid-Treatment (4 weeks) Post-Treatment (8 weeks), 6-months
Measures the extent to which a person can tolerate any distress associated with physical activity
Baseline, Mid-Treatment (4 weeks) Post-Treatment (8 weeks), 6-months
Change in Physical activity-related motivation (Treatment Self-Regulation Questionnaire - Exercise Version)
Time Frame: Baseline, Mid-Treatment (4 weeks) Post-Treatment (8 weeks), 6-months
Measures the extent to which a person is motivated to engage in physical activity
Baseline, Mid-Treatment (4 weeks) Post-Treatment (8 weeks), 6-months
Change in Discomfort intolerance (Discomfort Intolerance Scale)
Time Frame: Baseline, Mid-Treatment (4 weeks) Post-Treatment (8 weeks), 6-months
Measures the extent to which a person can tolerate uncomfortable experiences
Baseline, Mid-Treatment (4 weeks) Post-Treatment (8 weeks), 6-months
Change in Physical activity enjoyment (PACES questionnaire)
Time Frame: Baseline, Mid-Treatment (4 weeks) Post-Treatment (8 weeks), 6-months
Measures the extent to which a person enjoys physical activity
Baseline, Mid-Treatment (4 weeks) Post-Treatment (8 weeks), 6-months
Change in Credibility and expectancy questionnaire
Time Frame: Week 1 (After the first treatment session)
Measures perceived credibility and expected benefits of treatment
Week 1 (After the first treatment session)
Change in Client satisfaction questionnaire
Time Frame: Post-Treatment (8 weeks) and following the booster session (12 weeks)
Measures satisfaction with treatment
Post-Treatment (8 weeks) and following the booster session (12 weeks)
Change in Group cohesion questionnaire
Time Frame: Post-Treatment (8 weeks)
Measures perceived cohesiveness of the treatment group
Post-Treatment (8 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Da M Wil, Ph.D., Brown University School of Public Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 7, 2022

Primary Completion (Anticipated)

May 31, 2023

Study Completion (Anticipated)

August 31, 2023

Study Registration Dates

First Submitted

May 31, 2022

First Submitted That Met QC Criteria

June 3, 2022

First Posted (Actual)

June 7, 2022

Study Record Updates

Last Update Posted (Actual)

July 20, 2022

Last Update Submitted That Met QC Criteria

July 18, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • R34AT011302 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Physical Inactivity

Clinical Trials on ACTivity

3
Subscribe